DNA encoding a human dopamine D1 receptor and uses thereof
This invention provides isolated nucleic acid molecules encoding a human dopamine D 1 receptor, isolated proteins which are human dopamine D 1 receptor, vectors comprising isolated nucleic acid molecules encoding a human dopamine D 1 receptor, mammalian cells comprising such vectors, antibodies directed to a human dopamine D 1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human dopamine D 1 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human dopamine D 1 receptor, pharmaceutical compounds related to human dopamine D 1 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant human dopamine D 1 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving a human dopamine D 1 receptor.
1. A method for determining whether a ligand not known to be capable of binding to a human dopamine D 1β receptor can bind to a human dopamine D 1β receptor which comprises contacting a mammalian cell transfected with and expressing the human dopamine D 1β receptor on the surface of such cell, or contacting a membrane preparation of such a cell, with the ligand under conditions permitting binding of ligands known to bind to a human dopamine D 1β receptor, detecting the presence of any of the ligand bound to the human dopamine D 1β receptor, and thereby determining whether the ligand binds to a human dopamine D 1β receptor; wherein the human dopamine D 1β receptor has the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence identical to that encoded by the nucleic acid sequence contained in plasmid pdop-D1-GL-30 (ATCC Accession No. 40839).
2. The method of claim 1 , wherein the mammalian cell is nonneuronal in origin.
3. The method of claim 2 , wherein the mammalian cell nonneuronal in origin is an Ltk-cell.
4. A method of screening drugs to identify drugs which specifically interact with, and bind to, the human dopamine D 1β receptor which comprises contacting a mammalian cell transfected with and expressing the human dopamine D 1β receptor on the surface of such cell, or contacting a membrane preparation of such a cell, with a plurality of drugs, determining those drugs which bind to the mammalian cell, and thereby identifying drugs which specifically interact with, and bind to, the human dopamine D 1β receptor, wherein the human dopamine D 1β receptor has the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence identical to that encoded by the nucleic acid sequence contained in plasmid pdop-D1-GL-30 (ATCC Accession No. 40839).
5. The method of claim 4 , wherein the mammalian cell is nonneuronal in origin.
6. The method of claim 5 wherein the mammalian cell nonneuronal in origin is an Ltk-cell.